The Delirium Market size was valued at USD 0.320 Billion in 2023 and is projected to grow from USD 0.338 Billion in 2024 to USD 0.512 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.30% during the forecast period (2024 - 2032). Growing aging population, Improved identification and diagnosis, and technological advancements are driving the market growth.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The aging population is a significant driver of the delirium market. As the global population experiences a demographic shift towards older adults, the prevalence of delirium increases. Older individuals are more susceptible to delirium due to factors such as underlying health conditions, cognitive impairments, polypharmacy, and hospitalization. The physiological changes associated with aging, such as alterations in neurotransmitters and decreased cognitive reserve, also contribute to the vulnerability to delirium. The aging population's impact on the delirium market is multifaceted. Firstly, it leads to a greater number of delirium cases, creating a higher demand for diagnostic tools, interventions, and management strategies. Secondly, the complex medical needs of older patients require tailored approaches to delirium prevention and management. This drives the development of specialized programs, protocols, and guidelines for geriatric delirium care. In October 2022, according to the WHO, the number of people 60 and older will rise from 1 Million in 2020 to 1.4 Million. The number of people 60 and older in the world will double (2.1 Million) by the year 2050. Between 2020 and 2050, there will be 426 million more people who are 80 years of age or older.
Additionally, the aging population influences research and development efforts focused on understanding the underlying mechanisms of delirium and developing age-specific interventions. It also highlights the importance of interdisciplinary collaboration and training to equip healthcare professionals with the knowledge and skills necessary for effective delirium management in older adults. Overall, the growing aging population is a driving force behind the expansion and advancement of the delirium market.
The Delirium Market segmentation, based on type, includes Hyperactive, Hypoactive, Mixed. The Hypoactive segment is to hold the majority share in 2022 in the Delirium Market revenue. Due to hypoactive characterized by subdued motor activity, poses a unique challenge, necessitating specialized interventions. Pharmaceutical advancements and targeted therapeutic approaches are driving innovation in this market, providing novel treatment options. Healthcare providers are increasingly recognizing the importance of early detection and tailored interventions for hypoactive delirium, contributing to market expansion.
January 7, 2019: Dr. Lata McGinn, Cognitive Behavioural Consultants and Professor at Yeshiva University, announced the launch of the New International Cognitive Behaviour Therapy Organization. The organization is dedicated to the promotion of health and well-being through the scientific development and implementation of evidence-based cognitive behavioural strategies designed to evaluate, prevent, and treat mental conditions and illnesses.
The Delirium Market segmentation is based on a Diagnosis and treatment, that includes Diagnosis, and Treatment. The diagnosis segment has dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to integration of artificial intelligence and machine learning algorithms revolutionizing diagnostic approaches, offering more efficient and objective assessments. The growing emphasis on early detection and intervention is driving investments in research and development, fostering a dynamic landscape for diagnostic innovations in the Delirium Market, ultimately improving patient care and outcomes.
Figure 2: DELIRIUM MARKET, BY INDICATION, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The Delirium Market segmentation is based on end-user that includes Hospitals, Speciality Care, and Research Centers. The hospitals segment has dominated the market in 2022 and homecare is projected to be the fastest-growing segment during the forecast period, 2024-2032. This is due to hospitals increasingly recognizing the significance of delirium in patient care, there is a growing demand for effective solutions and interventions. Delirium management has become a focal point in hospitals, driven by factors such as an aging population and the recognition of delirium's impact on healthcare outcomes. Hospitals are investing in staff training, awareness programs, and specialized resources to address delirium promptly. The integration of comprehensive delirium protocols within hospital workflows is contributing to improved patient care, creating a positive trajectory for the growth of delirium-related services and products in the global healthcare landscape.
By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Delirium market accounted for the largest market share in 2022 due to aging population and a rise in chronic illnesses, there is an increased awareness of delirium as a critical aspect of patient care. The region's well-established healthcare infrastructure and advanced medical research contribute to the growth of diagnostic and therapeutic innovations in delirium management. Hospitals and healthcare facilities across North America are integrating specialized protocols, training programs, and advanced technologies to enhance delirium diagnosis and treatment.
Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: DELIRIUM MARKET BY REGION 2022 & 2032
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe Delirium market is expected to account for the second-largest market share due to the favorable health policies and trend towards integrating health services, including counseling. Further, the German Delirium market was attributed to holding the largest market share, and France Delirium market is expected to fastest-growing market in the European region.
The Asia-Pacific healthcare counseling market is expected to grow at the fastest rate from 2024 to 2032. This is due to the rising spending in healthcare, quickly evolving healthcare infrastructure, growing awareness regarding Delirium, and growing population in the region. Moreover, China’s Delirium market is expected to hold the largest market share, and India Delirium market is expected fastest-growing market in the Asia-Pacific region.
The Rest of the World includes the Middle East, Africa, and Latin America. The main factors influencing the growth of Delirium are in the Middle East and Africa. As the region experiences population growth and an increase in age-related conditions, the awareness and recognition of delirium as a significant healthcare concern are on the rise. Healthcare providers in the Middle East and Africa are progressively focusing on implementing effective diagnostic and therapeutic strategies for delirium management.
Delirium Key Market Players & Competitive Insights
The Delirium Market is characterized by the presence of many global, regional, players. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reached across the globe with diverse Type portfolios. Companies such as Otsuka Pharmaceutical Co., Ltd (Japan), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Zydus Group (India), Glenmark Pharmaceuticals Ltd (India), Pfizer (India), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Novartis AG (Switzerland) dominate the Delirium Market due to Type differentiation, financial stability, strategic services, and diversified regional presence. The players are focused on investing in extensive research and development as well. Furthermore, they adopt strategic growth initiatives, such as expansion, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.
One of the primary business strategies adopted by manufacturers in the global Delirium industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs.
Key Companies in the Delirium Market include
Delirium Industry Developments
April 2023, Otsuka Pharmaceutical Co., Ltd (Japan) got approval from US Food and Drug Administration for drug ABILIFY ASIMTUFII (aripiprazole) approval for the treatment of schizophrenia or delirium as well as maintenance monotherapy in people with bipolar I disorder. Moreover, this drug effectively treats delirium.
In April 2023, The US Food and Drug Administration approved Teva Pharmaceutical Industries’ UZEDY (risperidone) an injectable suspension, a long-acting subcutaneous atypical antipsychotic injection, for the treatment of schizophrenia and delirium in adults. Additionally, those who are physically ill could use this medication to decrease the behavioral and cognitive symptoms of delirium.
In September 2022, Ceribell, Inc (US) received US FDA breakthrough device designation from its device Ceribell system for the treatment of delirium indication. This device operates machine learning to examine electroencephalography (EEG) signals to detect delirium.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.320 Billion |
| Market Size 2024 | USD 0.338 Billion |
| Market Size 2032 | USD 0.512 Billion |
| Compound Annual Growth Rate (CAGR) | 5.30% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2019 to 2021 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Diagnosis and treatment, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Otsuka Pharmaceutical Co., Ltd (Japan), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Zydus Group (India), Glenmark Pharmaceuticals Ltd (India), Pfizer (India), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Novartis AG (Switzerland) |
| Key Market Opportunities | ·      Diagnostic Tools and Technologies·      Educational and Training Programs |
| Key Market Dynamics | ·      Growing aging population·      Improved identification and diagnosis·      Technological advancements |
Delirium Market Highlights:
Frequently Asked Questions (FAQ) :
The Delirium Market is anticipated to reach 0.512 billion at a CAGR of 5.84% during the forecast period of 2023-2032.
The US is expected to hold a 70-80% share of the North American market for the Delirium market during the forecast period of 2023-2032.
The Delirium market is expected to grow at a 5.30% CAGR during the forecast period from 2024 to 2032.
The North American region market held the largest market share in the Delirium market.
The key players include Otsuka Pharmaceutical Co., Ltd (Japan), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Zydus Group (India), Glenmark Pharmaceuticals Ltd (India), Pfizer (India), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Novartis AG (Switzerland).
The diagnosis segment was estimated to lead the Delirium market.
The Hospitals segment is attributed to having the largest market share based on end user.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
